Neuralink Demonstrates Thought-to-Speech in ALS Patient Through VOICE Trial

Neuralink demonstrated thought-to-speech technology in ALS patient Kenneth Shock, the second participant in its VOICE clinical trial implanted in January 2026.

Neuralink Demonstrates Thought-to-Speech in ALS Patient Through VOICE Trial Neuralink demonstrated thought-to-speech technology in ALS patient Kenneth Shock, the second participant in its VOICE clinical trial implanted in January 2026. Aaron Rafferty March 28, 2026 Key Takeaways: Neuralink demonstrated its N1 brain implant converting neural signals into audible speech for Kenneth Shock, an ALS patient who lost the ability to speak, as part of the VOICE clinical trial. The implant, placed in January 2026, decodes brain activity associated with speech, maps it to phonemes, and reproduces words in Shock's own pre-ALS voice. Neuralink has announced 21 total participants across its clinical programs, with high-volume implant production and automated surgical robotics planned for 2026. Kenneth Shock lost his ability to speak to ALS. This week, Neuralink showed him speaking again , not with his mouth but with his mind. — (@) The demonstration, shared on March 24, showed Shock communicating through Neuralink's N1 brain implant. The device, implanted in January 2026 as part of the VOICE clinical trial , captures neural activity in brain regions that control the speech apparatus and maps those signals to phonemes, the smallest units of sound. The system reconstructs words and vocalizes them through a computer, using Shock's own voice from before ALS degraded it. The process involved three stages. First, Shock spoke sentences aloud so the system could learn the correlation between brain activity and words. Then he repeated them silently, moving only his lips. In the final stage, the software recognized his intended speech with no mouth movement at all. Elon Musk posted that Neuralink is restoring speech to those who have lost the ability to speak. The technology